| Huang, He |
NCT05414006: Effect of S-ketamine in Cesarean Section Combined Anesthesia |
|
|
| Completed | 4 | 120 | RoW | S-ketamine, Patient controlled analgesia | The Second Affiliated Hospital of Chongqing Medical University | Postoperative Pain | 08/22 | 09/22 | | |
NCT05458453: An Exploratory Study of Esketamine in Patients After Thoracoscopic Surgery |
|
|
| Completed | 4 | 80 | RoW | Esketamine | The Second Affiliated Hospital of Chongqing Medical University | Esketamine, Thoracoscopic Surgery | 02/23 | 02/23 | | |
NCT05533281: Efficacy of Three Antiemetics in Preventing Nausea and Vomiting |
|
|
| Completed | 4 | 200 | RoW | tropisetron, metoclopramide, dexamethasone, normal saline | The Second Affiliated Hospital of Chongqing Medical University | Nausea and Vomiting | 10/23 | 11/23 | | |
NCT05265507: Comparison of Postoperative Anti-nausea and Vomiting Effect Between Glycopyrronium and Ondansetron |
|
|
| Recruiting | 4 | 480 | RoW | Glycopyrronium, Ondansetron | The Second Affiliated Hospital of Chongqing Medical University, Chongqing University Jiangjin Hospital, Chongqing Medical University, The People's Hospital of DAZU ，Chongqing, Xiangya Hospital of Central South University, West China Hospital, The People's Hospital of Tongliang District， Chongqing city, Chongqing Medical Center for Women and Children, Dianjiang People's Hospital of Chongqing, The Ninth People's Hospital of Chongqing, The People's Hospital of Yubei District of Chongqing city, Chongqing Yongchuan District People's Hospital, The First People's Hospital Of Chongqing Liang Jiang New Area, ChongGang General Hospital, The People's Hospital of Nanchuan, People's Hospital of Pengshui County, Yunyang people's Hospital, Chongqing Liangping District People's Hospital, Jiulongpo People's Hospital of chongqing, The People's Hospital of Qijiang District，Chongqing, University-Town Hospital of Chongqing Medical University, Chongqing Public Health Medical Center, CHONGQING BANAN HOSPITAL OF TCM | Postoperative Nausea and Vomiting | 05/23 | 05/23 | | |
NCT05331651: Effect of Glycopyrronium in Combination With Tropisetron in Anti-postoperative Nausea and Vomiting |
|
|
| Completed | 4 | 480 | RoW | Glycopyrronium in Combination With Tropisetron, Normal Saline in Combination With Tropisetron | The Second Affiliated Hospital of Chongqing Medical University, Chongqing General Hospital, Chongqing Medical University, The People's Hospital of DAZU ，Chongqing, The People's Hospital of Chongqing Kaizhou District, Fuling Hospital affiliated to Chongqing University, Qianjiang Central Hospital of Chongqing, Stomatological Hospital of Chongqing Medical University, People's Hospital of Changshou Chongqing, The Ninth People's Hospital of Chongqing, The First People's Hospital Of Chongqing Liang Jiang New Area, People's Hospital of Xiushan County, Wushan County People's Hospital, Three Gorges Hospital of Chongqing University, First Affiliated Hospital of Chongqing Medical University, Department of Anesthesiology, Daping Hospital, Institute of Surgery Research, the Army Medical University, The People's Hospital of Nanchuan, Chongqing Traditional Chinese Medicine Hospital, People's Hospital of Shapingba District， Chongqing, Chongqing Liangping District People's Hospital, Chongqing Jiangbei Hospital of Traditional Chinese Medicine, People's Hospital of Chongqing Hechuan | Postoperative Nausea and Vomiting | 06/23 | 06/23 | | |
NCT06569953: Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chronic Pain After Thoracoscopic Pneumonectomy: a Multicenter, Randomized, Double-blind, Controlled Clinical Trial |
|
|
| Recruiting | 4 | 284 | RoW | Liposomal bupivacaine, Bupivacaine Hydrochloride | The Second Affiliated Hospital of Chongqing Medical University, Chongqing General Hospital, LanZhou University, Xiangya Hospital of Central South University, Sichuan Provincial People's Hospital | Acute Pain, Chronic Pain, Postoperative Pain | 08/25 | 08/25 | | |
NCT02633176: Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 120 | RoW | Cetuximab, Erbitux, Cisplatin, Docetaxel, Taxotere, Capecitabine, Xeloda, Radiotherapy | Sun Yat-sen University, Chinese Southwest Oncology Group | Nasopharyngeal Carcinoma | 01/23 | | | |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Active, not recruiting | 3 | 440 | Europe, Canada, Japan, US, RoW | Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin | ADC Therapeutics S.A., ADC Therapeutics SA | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 06/25 | 06/28 | | |
|
|
|
| Active, not recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 02/25 | 08/28 | | |
ABSK021-201, NCT06186804: A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD) |
|
|
| Enrolling by invitation | 2 | 64 | RoW | ABSK021 | Abbisko Therapeutics Co, Ltd | cGvHD | 10/26 | 12/26 | | |
NCT04661020: CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 36 | RoW | CD19 CAR-T cells, CD19 CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Non-hodgkin Lymphoma,B Cell | 12/26 | 12/26 | | |
NCT04788472: Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL |
|
|
| Completed | 2 | 28 | RoW | CAR-T cells targeting CD19 and CD22 | Zhejiang University, Yake Biotechnology Ltd. | B-Cell Acute Lymphoblastic Leukemia, Adult | 08/24 | 08/24 | | |
NCT05712083: A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma |
|
|
| Recruiting | 2 | 40 | RoW | BCMA CAR-T cells, BCMA CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Multiple Myeloma, New Diagnosis Tumor | 04/24 | 04/24 | | |
NCT06300320: A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease |
|
|
| Recruiting | 2 | 40 | RoW | TQ05105 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Graft Versus Host Disease | 10/25 | 04/26 | | |
NCT05827835: CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases |
|
|
| Recruiting | 2 | 30 | RoW | CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation | Zhejiang University, Yake Biotechnology Ltd. | Hematologic Diseases, Neoplasms | 04/25 | 04/25 | | |
NCT04626908: Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma |
|
|
| Not yet recruiting | 1/2 | 18 | RoW | GC022F CAR-T cells, GC022F CAR-T cells injection | He Huang, Gracell Biotechnology Ltd. | Relapsed and Refractory, Lymphoid Hematological Malignancies | 06/22 | 06/23 | | |
FUMANBA-1, NCT05066646: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 132 | RoW | CT103A | Nanjing IASO Biotherapeutics Co.,Ltd | Multiple Myeloma | 10/22 | 06/24 | | |
NCT04944043: A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease |
|
|
| Active, not recruiting | 1/2 | 45 | RoW | TQ05105 Tablet | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Graft Versus Host Disease | 06/23 | 12/24 | | |
NCT06182696: OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM |
|
|
| Recruiting | 1/2 | 83 | RoW | OriCAR-017 | OriCell Therapeutics Co., Ltd. | Relapsed and/or Refractory Multiple Myeloma | 11/26 | 08/28 | | |
NCT06235229: A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 110 | RoW | GC012F | Gracell Biotechnologies Ltd. | Multiple Myeloma | 03/26 | 06/26 | | |
NCT04740203: Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL |
|
|
| Recruiting | 1/2 | 50 | RoW | CAR-T cells targeting CD19 and CD22 | Zhejiang University, Yake Biotechnology Ltd. | B-Cell Acute Lymphoblastic Leukemia, Adult | 01/24 | 01/25 | | |
NCT04790747: Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions |
|
|
| Recruiting | 1/2 | 50 | RoW | CAR-T cells | Zhejiang University, Yake Biotechnology Ltd. | Hematological Malignancies | 03/24 | 03/25 | | |
NCT06118788: Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1/2 | 24 | RoW | BG1805 | Guangzhou Bio-gene Technology Co., Ltd | Leukemia, Myeloid, Acute | 03/25 | 07/25 | | |
NCT04812691: CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma |
|
|
| Completed | 1 | 12 | RoW | JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells) | Shanghai Ming Ju Biotechnology Co., Ltd. | Diffuse Large B Cell Lymphoma | 06/21 | 04/23 | | |
NCT04516551: Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT |
|
|
| Recruiting | 1 | 18 | RoW | anti-CD19 allo-CAR-T cells | Xinqiao Hospital of Chongqing, Gracell Biotechnologies (Shanghai) Co., Ltd, First Affiliated Hospital of Zhejiang University, The Second Affiliated Hospital of Chongqing Medical University, The Affiliated Hospital Of Guizhou Medical University, The General Hospital of Western Theater Command, Chongqing University Cancer Hospital, The First Affiliated Hospital of Anhui Medical University, Tang-Du Hospital, 920th Hospital of Joint Logistics Support ForceFirst | Relapsed Adult ALL, B Cell Leukemia | 12/21 | 12/22 | | |
NCT04227015: A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy |
|
|
| Recruiting | 1 | 72 | RoW | CTA101, CTA101 UCAR-T cell injection | He Huang, Nanjing Bioheng Biotech Co., Ltd. | Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma | 01/22 | 05/27 | | |
NCT04226989: A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy |
|
|
| Recruiting | 1 | 72 | RoW | CT-RD06, CT-RD06 CAR-T cell injection | He Huang, Nanjing Bioheng Biotech Co., Ltd. | Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma | 02/22 | 05/24 | | |
NCT05030779: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 9 | RoW | Assigned Interventions CD19/BCMA CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | Systemic Lupus Erythematosus, Autoimmune Diseases | 03/22 | 09/22 | | |
NCT04599556: Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy |
|
|
| Recruiting | 1 | 81 | RoW | anti-CD7 CAR-T | Zhejiang University, Yake Biotechnology Ltd. | CD7+ Acute Leukemia, CD7+ Lymphoma | 12/23 | 12/25 | | |
PG-CART-07-001, NCT05170568: PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies |
|
|
| Recruiting | 1 | 22 | RoW | T cell injection targeting CD7 chimeric antigen receptor, PA3-17 injection | PersonGen BioTherapeutics (Suzhou) Co., Ltd., The First Affiliated Hospital of Zhengzhou University, Peking University People's Hospital, Union Hospital, affiliated with TongJi Medical College, HuaZhong University of Science and Technology, Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences), First Affiliated Hospital of Zhejiang University School of Medicine | CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies | 12/22 | 12/24 | | |
NCT04689204: A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies |
|
|
| Recruiting | 1 | 72 | RoW | CTA30X, CTA30X cell injection | He Huang, Nanjing Bioheng Biotech Co., Ltd. | Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma | 12/22 | 05/27 | | |
NCT04283006: A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies |
|
|
| Recruiting | 1 | 100 | RoW | CD20/CD22 dual Targeted CAR T-cells, CD20/CD22 dual Targeted CAR T-cells injection | He Huang, Yake Biotechnology Ltd. | Relapsed and Refractory, Lymphoid Hematological Malignancies | 05/23 | 05/28 | | |
NCT04532268: A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL |
|
|
| Recruiting | 1 | 72 | RoW | Humanized CD19 CAR-T cells, Humanized CD19 CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma,B Cell | 08/23 | 08/26 | | |
NCT05731219: UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 18 | RoW | B7-H3 target, CAR gene modified gdT cell injection, UTAA06 injection | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Relapsed/Refractory Acute Myeloid Leukemia | 09/23 | 09/25 | | |
NCT05846347: Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 15 | RoW | GC012F injection, CD19-BCMA CAR-T cells | Zhejiang University, Gracell Biotechnology Shanghai Co., Ltd. | CAR-T | 10/23 | 04/25 | | |
NCT04532203: A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies |
|
|
| Recruiting | 1 | 72 | RoW | CAR-T cells, CAR-T cells injection, Ommaya Reservoir | Zhejiang University | Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma | 11/23 | 11/26 | | |
NCT04532281: A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies |
|
|
| Recruiting | 1 | 120 | RoW | Murine CD19 CAR-T cells, Murine CD19 CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma of Soft Tissue | 11/23 | 11/26 | | |
NCT04603872: CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies |
|
|
| Recruiting | 1 | 120 | RoW | CD19/BCMA Targeted CAR T-cells and dasatinib, Administration of CD19/BCMA Targeted CAR T-cells and dasatinib, CD19/BCMA Targeted CAR T-cells, CD19/BCMA Targeted CAR T-cells infusion | Zhejiang University, Yake Biotechnology Ltd. | Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphocytic Leukaemia Refractory, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory | 11/23 | 11/26 | | |
NCT04599543: IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia |
|
|
| Not yet recruiting | 1 | 36 | RoW | IL3 CAR T-cells, IL3 CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Acute Myeloid Leukemia | 11/23 | 11/26 | | |
NCT04609241: CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma |
|
|
| Not yet recruiting | 1 | 72 | RoW | CD79b CAR-T Cells | Zhejiang University, Yake Biotechnology Ltd. | Relapsed and/or Refractory Acute Lymphoblastic Leukemia, Relapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma | 11/23 | 11/26 | | |
| Recruiting | 1 | 18 | RoW | QN-030a, Cyclophosphamid, Fludarabine, Cytarabine, VP-16 | Zhejiang University, Hangzhou Qihan Biotech Co.,Ltd. | AML, Adult | 12/23 | 12/25 | | |
NCT05665075: Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 19 | RoW | QN-023a, Cyclophosphamid, Fludarabine, Cytarabine, VP-16 | Zhejiang University, Hangzhou Qihan Biotech Co.,Ltd. | AML, Adult | 12/23 | 12/25 | | |
NCT04541368: A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy |
|
|
| Not yet recruiting | 1 | 50 | RoW | CS1 Targeted CAR T-cells, CS1 Targeted CAR T-cells injection | Zhejiang University, Yake Biotechnology Ltd. | Relapse Multiple Myeloma | 12/23 | 12/26 | | |
| Recruiting | 1 | 156 | US, RoW | CS5001 | CStone Pharmaceuticals | Advanced Solid Tumor, Advanced Lymphoma | 03/25 | 06/25 | | |
|
NCT04670055: A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma |
|
|
| Not yet recruiting | 1 | 50 | RoW | BCMA Targeted CAR T-cells, BCMA Targeted CAR T-cells injection | Zhejiang University, Yake Biotechnology Ltd. | Relapse Multiple Myeloma, Refractory Multiple Myeloma | 01/24 | 01/27 | | |
NCT04662294: CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases |
|
|
| Recruiting | 1 | 108 | RoW | CD70 CAR T-cells, CD70 CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Acute Myeloid Leukemia, Non-hodgkin's Lymphoma, Multiple Myeloma | 01/24 | 01/27 | | |
| Recruiting | 1 | 18 | RoW | CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection, BRL-201 | Bioray Laboratories, Institute of Hematology ＆ Blood Diseases Hospital，Chinese Academy of Medical Sciences, Zhejiang University, Wuhan Union Hospital, China | Non-hodgkin Lymphoma,B Cell | 01/24 | 03/24 | | |
NCT05349266: Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy |
|
|
| Recruiting | 1 | 16 | RoW | ThisCART19A | Zhejiang University | Non-Hodgkin's Lymphoma | 03/24 | 04/24 | | |
NCT05350852: Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL |
|
|
| Recruiting | 1 | 16 | RoW | ThisCART19A | Zhejiang University | B-ALL | 03/24 | 04/24 | | |
FT400-004, NCT05350787: Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL |
|
|
| Recruiting | 1 | 16 | RoW | ThisCART19A | Zhejiang University | B-ALL | 03/24 | 04/24 | | |
NCT05340829: Evaluate the Safety and Effect of ThisCART19A in Patients With AIDS Related B Cell Lymphoma/Lympholeukemia |
|
|
| Recruiting | 1 | 18 | RoW | ThisCART19A | He Huang | AIDS Related Lymphoma and Lympholeukemia | 03/24 | 04/24 | | |
NCT06279923: CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases |
|
|
| Recruiting | 1 | 45 | RoW | CD19-BAFF Targeted CAR T-cells, CD19-BAFF Targeted CAR T-cells injection | Zhejiang University, Shanghai YaKe Biotechnology Ltd. | Autoimmune Diseases | 02/27 | 02/27 | | |
NCT06367673: Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 24 | RoW | iPSC-NK cells | Zhejiang University, Hangzhou Qihanjiyin Biotech Co.,Ltd. | AML, Adult | 03/26 | 08/26 | | |
NCT06346912: CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL |
|
|
| Recruiting | 1 | 20 | RoW | CD19-BAFF Targeted CAR T-cells, CD19-BAFF Targeted CAR T-cells injection | Zhejiang University, Shanghai YaKe Biotechnology Ltd. | Acute Lymphoblastic Leukemia,B-Cell, Non-hodgkin Lymphoma,B Cell | 05/27 | 05/27 | | |
NCT05379647: Natural Killer (NK) Cell Therapy for B-Cell Malignancies |
|
|
| Recruiting | 1 | 24 | RoW | QN-019a, Rituximab, Cyclophosphamid, Fludarabine, VP-16 | Zhejiang University, Hangzhou Qihan Biotech Co.,Ltd. | B-cell Lymphoma, B-cell Acute Lymphoblastic Leukemia | 06/24 | 12/24 | | |
NCT06119659: Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001 |
|
|
| Not yet recruiting | 1 | 9 | NA | Low dose KL001, rAAV vector, Middle dose KL001, High dose KL001 | Zhejiang University | Hemophilia B Without Inhibitor | 06/24 | 07/25 | | |
NCT05444322: A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 1 | 18 | RoW | RD14-01 cell infusion | He Huang | Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Follicular Lymphoma | 07/24 | 07/25 | | |
| Not yet recruiting | 1 | 20 | RoW | CLL1 CAR-T | Zhejiang University | AML | 08/24 | 08/25 | | |
NCT05463640: Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With R/R AML |
|
|
| Not yet recruiting | 1 | 20 | RoW | ADGRE2 CAR-T | Zhejiang University | AML | 08/24 | 08/25 | | |
| Not yet recruiting | 1 | 20 | RoW | CLL1+CD33 CAR-T | Zhejiang University | AML | 08/24 | 08/25 | | |
NCT05473221: Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML |
|
|
| Not yet recruiting | 1 | 20 | RoW | CD33 CAR-T | Zhejiang University | AML | 08/24 | 08/25 | | |
NCT04657861: APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 36 | RoW | APRIL CAR-T cells, APRIL CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | 08/24 | 08/27 | | |
NCT05263817: A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis |
|
|
| Recruiting | 1 | 75 | RoW | CD19/BCMA CAR T-cells, CD19/BCMA CAR T-cells injection | Zhejiang University, Yake Biotechnology Ltd. | POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, Vasculitis | 10/24 | 10/24 | | |
NCT05085444: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma |
|
|
| Recruiting | 1 | 9 | RoW | Assigned Interventions CD19/BCMA CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | Scleroderma, Autoimmune Diseases | 10/24 | 10/24 | | |
NCT06633341: Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma |
|
|
| Recruiting | 1 | 30 | RoW | CD5 CAR T-cells, CD5+ T-lymphoma Targeted CAR T-cells injection | Zhejiang University, Shanghai YaKe Biotechnology Ltd. | T-lymphoblastic Lymphoma | 10/27 | 10/27 | | |
NCT06633328: CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia |
|
|
| Recruiting | 1 | 30 | RoW | CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation | Zhejiang University, Shanghai YaKe Biotechnology Ltd. | Aplastic Anemia | 10/27 | 10/27 | | |
NCT06633354: Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL |
|
|
| Recruiting | 1 | 30 | RoW | CD5 CAR T-cells, CD5+ T-ALL Targeted CAR T-cells injection | Zhejiang University, Shanghai YaKe Biotechnology Ltd. | T-Acute Lymphoblastic Leukemia | 10/27 | 10/27 | | |
NCT06644118: A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Recruiting | 1 | 58 | RoW | OL-101 infusion | Zhejiang University, Overland Therapeutics | Multiple Myeloma | 10/27 | 10/28 | | |
NCT05085431: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome |
|
|
| Recruiting | 1 | 9 | RoW | Assigned Interventions CD19/BCMA CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | Sjogren's Syndrome, Autoimmune Diseases | 11/24 | 11/24 | | |
NCT05085418: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis |
|
|
| Recruiting | 1 | 9 | RoW | Assigned Interventions CD19/BCMA CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | Immune Nephritis, Autoimmune Diseases, Lupus Nephritis | 11/24 | 11/24 | | |
| Recruiting | 1 | 36 | RoW | CLL1 CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | AML | 11/24 | 11/24 | | |
NCT05239676: Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma |
|
|
| Recruiting | 1 | 50 | RoW | Autologous hematopoietic stem cell transplantation combined with CD19 CAR-T cells | Zhejiang University, Yake Biotechnology Ltd. | Lymphoma | 12/24 | 12/24 | | |
NCT05239702: Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases |
|
|
| Recruiting | 1 | 75 | RoW | CD7 CAR T-cells, CD7 CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Crohn Disease, Ulcerative Colitis, Dermatomyositis, Still Disease, Autoimmune Diseases | 12/24 | 12/24 | | |
NCT06419166: An Exploratory Clinical Study of GC012F Injection for Refractory gMG |
|
|
| Not yet recruiting | 1 | 18 | RoW | GC012F injection | Zhejiang University, Gracell Biotechnologies (Shanghai) Co., Ltd. | Refractory Generalized Myasthenia Gravis | 06/27 | 10/27 | | |
NCT06711146: Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research |
|
|
| Recruiting | 1 | 36 | RoW | Metabolically Armed CD19 CAR-T cells, Meta10-19 | Zhejiang University, Leman Biotech Co., Ltd | Systemic Lupus Erythematosus | 12/26 | 04/27 | | |
Meta10-19-006, NCT06716164: Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research |
|
|
| Recruiting | 1 | 36 | RoW | Metabolically Armed CD19 CAR-T cells, Meta10-19 | Zhejiang University, Leman Biotech Co., Ltd | Non-hodgkin Lymphoma,B Cell | 12/26 | 04/27 | | |
NCT05239689: Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies |
|
|
| Recruiting | 1 | 36 | RoW | CD38 CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | AML | 12/24 | 12/24 | | |
| Recruiting | 1 | 23 | RoW | Chimeric Natural Killer Receptor Universal T-cells (CNK-UT) | First Affiliated Hospital of Zhejiang University, ST Phi Therapeutics Co., Ltd | Acute Graft-versus-Host Disease | 12/25 | 06/26 | | |
NCT06125106: Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab |
|
|
| Recruiting | 1 | 31 | RoW | Blinatumomab, HSCT | Zhejiang University | Acute Lymphoblastic Leukemia | 01/25 | 02/26 | | |
NCT06762119: A Study of CAR-T Cells in Subjects with Autoimmune Diseases |
|
|
| Not yet recruiting | 1 | 6 | RoW | CAR-T cell | Zhejiang University | Autoimmune Diseases | 08/27 | 11/27 | | |
NCT06762132: A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 27 | RoW | CD33 CAR T-cells, CD33 CAR T-cells injection | Zhejiang University, Shanghai YaKe Biotechnology Ltd. | Acute Myeloid Leukemia | 10/27 | 10/27 | | |
NCT06769191: Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treatment of SIOD |
|
|
| Recruiting | 1 | 20 | RoW | CD7 CAR-T cells injection, Allo-HSCT, Kidney Transplantation | Zhejiang University, Shanghai YaKe Biotechnology Ltd., BRL Medicine Inc. | Schimke Immuno-osseous Dysplasia | 01/28 | 01/28 | | |
NCT06793241: Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1 | 15 | RoW | CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells injection | Zhejiang University, Shanghai YaKe Biotechnology Ltd. | B-cell Acute Lymphoblastic Leukemia | 01/28 | 01/28 | | |
NCT05740891: AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma |
|
|
| Recruiting | 1 | 50 | RoW | BCMA CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Multiple Myeloma | 03/25 | 03/25 | | |
NCT05430945: A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma |
|
|
| Recruiting | 1 | 100 | RoW | BCMA Targeted CAR T-cells, BCMA Targeted CAR T-cells injection | Zhejiang University, Yake Biotechnology Ltd. | Relapse Multiple Myeloma, Refractory Multiple Myeloma | 06/25 | 06/25 | | |
NCT06120166: Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research |
|
|
| Recruiting | 1 | 18 | RoW | Metabolically Armed CD19 CAR-T cells, Meta10-19 | He Huang, Leman Biotech Co., Ltd | Diffuse Large B-cell Lymphoma | 12/25 | 04/26 | | |
NCT05828225: Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis |
|
|
| Recruiting | 1 | 9 | RoW | CD19 CAR-T cells injection | Zhejiang University | Myasthenia Gravis | 04/26 | 04/26 | | |
NCT05828212: Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica |
|
|
| Recruiting | 1 | 9 | RoW | CD19 CAR-T cells injection | Zhejiang University | Neuromyelitis Optica | 04/26 | 04/26 | | |
| Recruiting | 1 | 24 | RoW | CLL1 CAR-NK cell injection | Zhejiang University, Hangzhou Qihangene Biotech Co.,Ltd. | AML, Adult | 08/26 | 08/26 | | |
NCT06084962: A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma |
|
|
| Recruiting | 1 | 40 | RoW | DeepTag-GPRC5D Targeted CAR T-cells, DeepTag-GPRC5D Targeted CAR T-cells injection | He Huang, Yake Biotechnology Ltd. | Relapse/Refractory Multiple Myeloma | 10/26 | 10/26 | | |
NCT04448509: Peripheral Blood Mononuclear Cell Collection Protocol for UCART Cell Tumor Immunotherapy Study |
|
|
| Recruiting | N/A | 50 | RoW | Peripheral blood mononuclear cell apheresis | He Huang, Nanjing Bioheng Biotech Co., Ltd. | Peripheral Blood Mononuclear Cell | 07/20 | 08/22 | | |
| Completed | N/A | 20 | RoW | PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells, PD1-CD19-CART | Bioray Laboratories, First Affiliated Hospital of Zhejiang University | B-cell Lymphoma | 11/21 | 11/23 | | |
| Recruiting | N/A | 80 | US | Powered Prosthesis | North Carolina State University | Amputation | 12/24 | 05/25 | | |
NCT05392426: Left Ventricular Global Longitudinal Strain and Postoperative Myocardial Injury |
|
|
| Recruiting | N/A | 58 | RoW | Left Ventricular Global Longitudinal Strain, EF CO SV EDV ESV | The Second Affiliated Hospital of Chongqing Medical University | Postoperative Complications | 12/22 | 06/23 | | |
NCT05548153: An Observational Study on the Relationship Between Tear Metabolomics and POD |
|
|
| Completed | N/A | 150 | RoW | | The Second Affiliated Hospital of Chongqing Medical University | Postoperative Delirium | 03/23 | 03/23 | | |
NCT06281431: A Comparative Effect of Echogenic Needle for Nerve Block on Acute and Chronic Postoperative Pain |
|
|
| Recruiting | N/A | 1000 | RoW | Echogenic nerve block needle, Non-echogenic nerve block needle | The Second Affiliated Hospital of Chongqing Medical University | Chronic Postoperative Pain | 09/25 | 09/25 | | |
NCT06018246: Nutritional Risk Screening Nutritional Support Gastrointestinal Cancer |
|
|
| Completed | N/A | 624 | RoW | Malnutrition five-step treatment model + conventional nutritional intervention, Conventional nutritional intervention | The First Affiliated Hospital of Shanxi Medical University | Gastrointestinal Cancer | 06/23 | 07/23 | | |
HRISK, NCT05510388: HFNO Reduces Hypoxia During Sedated Gastroscopy or Colonoscopy in High Risk Patients |
|
|
| Not yet recruiting | N/A | 450 | RoW | High-flow nasal cannula oxygenation, Regular nasal cannula oxygenation | RenJi Hospital | Gastric Cancer, Intestinal Cancer, Intestine Adenoma, Gastritis | 06/23 | 06/23 | | |
